Regeneron - Crunchbase Company Profile & Funding

Q: Where is Regeneron's headquarters?

Regeneron is located in Tarrytown, New York, United States.

Q: When was the last funding round for Regeneron?

Regeneron closed its last funding round on obfuscated from a Post-IPO Equity round.

Q: How much funding has Regeneron raised to date?

Regeneron has raised obfuscated.

Overview

Regeneron

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

+5 more milestones

See more interactive data and historical milestones on desktop for the best experience

About Regeneron

CB Rank

2863

Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of innovative medicines.

Founded

obfuscation

Public

Post-IPO Equity

Tarrytown, New York, United States

10001+

www.regeneron.com

Biopharma

Biotechnology

Pharmaceutical

Funding Rounds

Post-IPO Equity

OBF

obfuscation

Post-IPO Equity

OBF

obfuscation

Post-IPO Equity

OBF

obfuscation

Key People

Nanita Cranford: Executive Director, Head of Global Regulatory Operations
Past Role: Jazz Pharmaceuticals, Senior Director, Regulatory Affairs, Head of Global Regulatory Operations
Aris Baras: Senior Vice President, Regeneron Pharmaceuticals, General Manager, Regeneron Genetics Center

Details

Legal Name

Regeneron Pharmaceuticals, Inc.

Operating Status

Active

Number of Exits

obfuscation

Stock Symbol

NASDAQ:REGN

Company Type

For Profit

Founders

Eric Shooter, George Yancopoulos, Leonard Schleifer

About the Company

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products to treat serious medical conditions. The company has therapeutic candidates in clinical trials for potentially treating cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and

disorders.

Phone Number

+118557343648

Predictions & Insights

Growth Insight

See this Growth Insight

Regeneron is

Lorem

to be growing

Top Contributing Factors

Financial Growth

Products & Services

Dupixent (dupilumab)

A monoclonal antibody medicine targeting IL-4R alpha subunit for treating allergic and inflammatory diseases.

EYLEA (aflibercept)

A trap protein medicine used to treat retinal diseases by inhibiting vascular endothelial growth factor (VEGF).

Research & Development

Regeneron is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Equity - Regeneron	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Regeneron	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Regeneron	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Regeneron	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Regeneron	—	obfuscated obfuscation	—	Post-IPO Equity

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Equity - Regeneron	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Regeneron	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Regeneron	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Regeneron	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Regeneron	—	obfuscated obfuscation	—	Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
U.S. Department of Health & Human Services	Yes	Post-IPO Equity - Regeneron	—
U.S. Department of Health & Human Services	Yes	Post-IPO Equity - Regeneron	—
U.S. Department of Health & Human Services	Yes	Post-IPO Equity - Regeneron	—
U.S. Department of Health & Human Services	Yes	Post-IPO Equity - Regeneron	—
U.S. Department of Health & Human Services	Yes	Post-IPO Equity - Regeneron	—

Investments

Investment Breakdown

Diversity Investments

Number of Funds

Number of Investments

Number of Exits

obfuscation

Number of Acquisitions

See investment data for this company, with details on deal size, industry, stage, and more.

Announced Date	Organization Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Parabilis Medicines	Yes	Post-IPO Equity - Parabilis Medicines	obfuscated obfuscation
obfuscated obfuscation	Parabilis Medicines	Yes	Post-IPO Equity - Parabilis Medicines	obfuscated obfuscation
obfuscated obfuscation	Parabilis Medicines	Yes	Post-IPO Equity - Parabilis Medicines	obfuscated obfuscation
obfuscated obfuscation	Parabilis Medicines	Yes	Post-IPO Equity - Parabilis Medicines	obfuscated obfuscation
obfuscated obfuscation	Parabilis Medicines	Yes	Post-IPO Equity - Parabilis Medicines	obfuscated obfuscation

Investment Breakdown

Number of Funds

Number of Investments

Number of Exits

obfuscation

Number of Acquisitions

See investment data for this company, with details on deal size, industry, stage, and more.

Announced Date	Organization Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Parabilis Medicines	Yes	Post-IPO Equity - Parabilis Medicines	obfuscated obfuscation
obfuscated obfuscation	Parabilis Medicines	Yes	Post-IPO Equity - Parabilis Medicines	obfuscated obfuscation
obfuscated obfuscation	Parabilis Medicines	Yes	Post-IPO Equity - Parabilis Medicines	obfuscated obfuscation
obfuscated obfuscation	Parabilis Medicines	Yes	Post-IPO Equity - Parabilis Medicines	obfuscated obfuscation
obfuscated obfuscation	Parabilis Medicines	Yes	Post-IPO Equity - Parabilis Medicines	obfuscated obfuscation

Diversity Investments

Number of Diversity Investments

Announced Date	Organization Name	Diversity Spotlight	Funding Round	Money Raised
obfuscated obfuscation	Parabilis Medicines	Women Founded	Post-IPO Equity - Parabilis Medicines	obfuscated obfuscation
obfuscated obfuscation	Mammoth Biosciences	Women Founded	Corporate Round - Mammoth Biosciences	obfuscated obfuscation
obfuscated obfuscation	Sonoma Biotherapeutics	Women Founded	Corporate Round - Sonoma Biotherapeutics	obfuscated obfuscation
obfuscated obfuscation	Vyriad	Women Founded	Series B - Vyriad	obfuscated obfuscation
obfuscated obfuscation	Adicet Bio	Women Founded	Series B - Adicet Bio	obfuscated obfuscation

Market Intelligence

People

View Profiles & Contacts

Headcount

10001+

Employee Profiles

Board Members and Advisors

Contacts

9,931

Employee Profiles

Nanita Cranford Executive Director, Head of Global Regulatory Operations
Aris Baras Senior Vice President, Regeneron Pharmaceuticals, General Manager, Regeneron Genetics Center
Gregory Geba Senior Vice President, Global Development Scientific Council
Michael Selzer Manager, Combination Products Engineering